Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Publication|Videos|May 13, 2024
Talking Strategic Development with Simtra at DCAT
Author(s)Simtra BioPharma Solutions
Ray Guidotti, Chief Operating Officer at Simtra BioPharma Solutions, talks about the company's strategic development and how it supports customers with a focus on excellence.
Simtra BioPharma Solutions is a premier contract development and manufacturing organization (CDMO) with more than 65 years of sterile injectable (SI) experience and a dedicated focus on providing a range of services from clinical development to commercial fill/finish. Learn more about:
- Simtra’s new building in Halle that features a high-speed syringe line and vial line equipped with four lyophilizers and is expected to be GMP ready in 2024.
- The new clinical line in Bloomington that will be ready to take on projects in the summer of 2025.
- Construction of the new state-of-the-art building in Bloomington that will begin in the summer of 2024.
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
AAPS PharmSci 360 2026: E&L Standards Harmonization
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5